These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20980796)

  • 1. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
    MacIntyre CR; Egerton T; McCaughey M; Parrino J; Campbell BV; Su SC; Pagnoni MF; Stek JE; Xu J; Annunziato PW; Chan IS; Silber JL
    Hum Vaccin; 2010 Nov; 6(11):894-902. PubMed ID: 20980796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
    Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
    Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
    J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
    Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
    Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
    Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
    Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
    Ofori-Anyinam O; Leroux-Roels G; Drame M; Aerssens A; Maes C; Amanullah A; Schuind A; Li P; Jain VK; Innis BL
    Vaccine; 2017 Nov; 35(46):6321-6328. PubMed ID: 28987445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant administration of pneumococcal-23 and zoster vaccines provides adequate herpes zoster coverage.
    Wyman MJ; Stabi KL
    Ann Pharmacother; 2013; 47(7-8):1064-8. PubMed ID: 23715069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children.
    Yetman RJ; Shepard JS; Duke A; Stek JE; Petrecz M; Klopfer SO; Kuter BJ; Schödel FP; Lee AW
    Hum Vaccin Immunother; 2013 Aug; 9(8):1691-7. PubMed ID: 23744509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older.
    Sutradhar SC; Wang WW; Schlienger K; Stek JE; Xu J; Chan IS; Silber JL
    Clin Vaccine Immunol; 2009 May; 16(5):646-52. PubMed ID: 19261769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
    Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
    Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.
    Schmader KE; Levin MJ; Gnann JW; McNeil SA; Vesikari T; Betts RF; Keay S; Stek JE; Bundick ND; Su SC; Zhao Y; Li X; Chan IS; Annunziato PW; Parrino J
    Clin Infect Dis; 2012 Apr; 54(7):922-8. PubMed ID: 22291101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
    Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
    J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.
    Benson CA; Andersen JW; Macatangay BJC; Mailliard RB; Rinaldo CR; Read S; Bozzolo DR; Purdue L; Jennings C; Keefer MC; Glesby M; Tebas P; Russell AF; Martin J; Annunziato P; Popmihajlov Z; Lennox JL
    Clin Infect Dis; 2018 Nov; 67(11):1712-1719. PubMed ID: 29590326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.
    Frenck RW; Gurtman A; Rubino J; Smith W; van Cleeff M; Jayawardene D; Giardina PC; Emini EA; Gruber WC; Scott DA; Schmöle-Thoma B
    Clin Vaccine Immunol; 2012 Aug; 19(8):1296-303. PubMed ID: 22739693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
    Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
    Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.
    Choi WS; Choi JH; Choi JY; Eom JS; Kim SI; Pai H; Peck KR; Sohn JW; Cheong HJ
    J Korean Med Sci; 2016 Jan; 31(1):13-7. PubMed ID: 26770032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
    Gilderman LI; Lawless JF; Nolen TM; Sterling T; Rutledge RZ; Fernsler DA; Azrolan N; Sutradhar SC; Wang WW; Chan IS; Schlienger K; Schödel F; Silber JL;
    Clin Vaccine Immunol; 2008 Feb; 15(2):314-9. PubMed ID: 18077611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.
    Macaladad N; Marcano T; Guzman M; Moya J; Jurado F; Thompson M; Meechan C; Li D; Schlienger K; Chan I; Sadoff J; Schödel F; Silber JL
    Vaccine; 2007 Mar; 25(11):2139-44. PubMed ID: 17250932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunogenicity and safety of zoster vaccine in Taiwanese adults.
    Yao CA; Chen LK; Huang KC
    Vaccine; 2015 Mar; 33(13):1515-7. PubMed ID: 25681662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.